MedRx Co., Ltd
Stock Price Chart
2026/10/07 19:11 UpdatedPrice Trend
2026/10/07 19:11 UpdatedPrice & Trading Details
2026/10/07 19:11 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/10/01Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥59M | ¥30M | ¥258M | ¥128M |
| Gross Profit | ¥57M | ¥27M | ¥258M | ¥127M |
| Operating Income | -¥1,099M | -¥934M | -¥793M | -¥942M |
| Pretax Income | -¥1,099M | -¥934M | -¥793M | -¥942M |
| Net Income | -¥1,111M | -¥933M | -¥807M | -¥937M |
| EPS | -¥43.81 | -¥26.82 | -¥18.56 | -¥17.44 |
| Operating Margin | -1,847.32% | -3,160.99% | -307.48% | -735.45% |
| Balance Sheet | ||||
| Total Assets | ¥1,398M | ¥2,052M | ¥2,276M | ¥2,158M |
| Total Equity | ¥1,213M | ¥1,925M | ¥2,170M | ¥2,049M |
| Total Liabilities | ¥186M | ¥128M | ¥106M | ¥109M |
| Cash | ¥994M | ¥1,721M | ¥1,978M | ¥1,755M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 86.73% | 93.79% | 95.36% | 94.97% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | -¥1,073M | -¥914M | -¥803M | -¥888M |
| Investing CF | -¥2M | -¥1M | -¥3M | -¥83M |
| Financing CF | ¥356M | ¥1,639M | ¥1,067M | ¥745M |
| Free CF | -¥1,075M | -¥915M | -¥804M | -¥971M |
| Efficiency | ||||
| ROE | -91.63% | -48.47% | -37.18% | -45.75% |
| ROA | -79.47% | -45.46% | -35.45% | -43.45% |
Latest IR Information
-
Notice Regarding Change of Market Segment to the Tokyo Stock Exchange "Standard" Market
On 2026-10-07, the company changed its market segment from the Tokyo Stock Exchange Growth Market to the Standard Market. There is no change in growth or R&D policy; the company confirms it will continue drug development leveraging its proprietary formulation...
Read more -
Notice Regarding Monthly Exercise Status of the 35th Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued by Third-Party Allotment
For the monthly exercise status, 14,770 stock acquisition rights were exercised in the target month, with an exercise ratio of 9.99%. Unexercised rights decreased to 41,395 rights (4,139,500 shares). Number of shares delivered in the target month: 1,477,000 shares. Unexercised...
Read more -
Regarding U.S. Sales Partnership with Terrain for "Bondlido" and Launch Timing
Regarding the U.S. sales partnership for Bondlido, the sales license agreement is expected to be concluded in October 2026, and the launch timing has been revised to the fourth quarter of 2026. The revenue scale is unknown, but market size...
Read more -
Notice of Monthly Exercise Status of the 35th Share Acquisition Rights Issued via Third-Party Allotment (Exercise Price Revision Clause)
Monthly exercise status for August 2026 disclosed. Total shares allocated for the target month: 2,323,000 shares; exercised share acquisition rights: 23,230 units; transfer treasury stock fluctuates between 2,264 and 600 shares. Unexercised shares at month-end: 5,616,500 shares; previous month-end: 7,939,500...
Read more -
Bondlido sales partnership in the United States with Terrain and timing of the listing
Regarding the Bondlido US sales partnership, the sales license agreement is expected to be signed in September, with上市 timing anticipated in Q4 2026. The contract term revisions are taking time, and the impact is considered minor.
Read more
Latest News (5 items)
Company Information
About
MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops transdermal medicines based on the ionic liquid transdermal system (ILTS) and the nano-sized colloid transdermal system (NCTS); and microneedle arrays/patch vaccines for the delivery of vaccines and APIs through the skin. Its products also include MRX-5LBT, which has NDA approval in the United States for neuropathic pain; MRX-4TZT, which is in a Phase II trial for spastic paralysis; Alto-101, which is in a Phase II trial for schizophrenia; MRX-9FLT, which is in a Phase I trial for moderate to severe pain; and MRX-6LDT, which is in a drug formulation development stage for chronic pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.
